Fisetin

Research Papers and Clinical Trials

Recent preclinical research on fisetin has explored its potential therapeutic applications across several disease areas, though human clinical evidence remains limited.

Preclinical Research

Laboratory studies have investigated fisetin's effects in neurodegenerative diseases, with one 2026 study examining its protective effects in cellular models of amyotrophic lateral sclerosis (ALS). The research used SH-SY5Y cells with specific genetic variants (G262R and P438L of SQSTM1) associated with ALS, though specific sample sizes and detailed methodologies are not provided in the available abstracts.

Cancer research has shown activity across multiple tumor types. A 2026 study developed nanostructured lipid carriers combining fisetin with flavokawain A for non-small cell lung cancer treatment, while another investigated glucose-capped fisetin silver nanoparticles in breast cancer cell models. The breast cancer study included proteomic profiling and analysis of RNA regulatory mechanisms, but sample sizes are not specified in available information.

Liver protection studies have examined fisetin's effects against chemical-induced injury. A 2026 mouse study investigated fisetin's protective effects against carbon tetrachloride (CCl4)-induced liver damage, focusing on TGF-β1/Smad3 and p53/Bax/Bcl-2 signaling pathways, though the number of animals studied is not reported.

Additional research has explored fisetin's role as a senotherapeutic agent (targeting cellular aging) and its anti-inflammatory properties, particularly in the context of neurodegeneration and ovarian aging.

Clinical Trials

Human clinical research on fisetin remains very limited. Five registered clinical trials have been identified, but most have encountered significant challenges:

• COVID-19 study (NCT04537299): A Phase 2 pilot study investigating fisetin in older adults in nursing homes with COVID-19 was terminated, with no results reported.

• Frailty study (NCT03430037): A Phase 2 trial examining fisetin's effects on frailty and inflammation in older women is currently enrolling participants by invitation only.

• Three additional trials investigating fisetin in knee osteoarthritis, meniscus repair, and general osteoarthritis have been either withdrawn or suspended before completion.

The limited clinical data means that while laboratory studies suggest potential therapeutic benefits, human efficacy and safety data for fisetin remain insufficient to draw clinical conclusions.

Note: This information is for educational purposes only and should not be considered medical advice. Consult healthcare providers for medical decisions.